Dr. Reddy's Laboratories

Corporate brand

Indian multinational pharmaceutical company focused on generic medicines, active pharmaceutical ingredients, branded formulations, biosimilars and selected innovative therapies.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad. Founded in 1984 by Kallam Anji Reddy, the company initially concentrated on manufacturing active pharmaceutical ingredients (APIs) for other drug makers. It subsequently expanded into finished formulations, branded medicines, generic pharmaceuticals, biosimilars, diagnostics, critical-care products and research-based therapies. The company grew during a period when India's pharmaceutical industry was developing stronger domestic manufacturing capabilities and using process innovation to serve markets with lower medicine costs. Its early international business supplied APIs and finished products to less-regulated markets, allowing Dr. Reddy's to build scale before investing in facilities and regulatory systems suitable for the United States and Europe. During the late 1980s and 1990s, it broadened its manufacturing base and began pursuing approvals in highly regulated markets. Important early products included Norilet, one of its first recognized Indian brands, and Omez, a branded omeprazole product positioned at a substantially lower price than competing products in India. The company also developed a strategy around abbreviated new drug applications and patent challenges, seeking earlier entry for generic medicines in the United States. Its 2001 launch of generic fluoxetine, with 180-day exclusivity for one dosage strength after successful patent litigation, became a major turning point in its U.S. business. Dr. Reddy's expanded through subsidiaries, partnerships and acquisitions. The acquisition of American Remedies in 1999 strengthened its Indian portfolio, while the purchase of BMS Laboratories and Meridian Healthcare in the United Kingdom and Betapharm Arzneimittel in Germany increased its European presence. Research and discovery activities were developed through the Dr. Reddy's Research Foundation, the U.S.-based Reddy US Therapeutics operation and Aurigene Discovery Technologies. Although the company explored new drug discovery, its core business model remained based on generics, APIs, branded formulations and specialty products. The company became the first non-Japanese pharmaceutical company in the Asia-Pacific region to list on the New York Stock Exchange, using American Depositary Receipts. Its international business includes generics for regulated markets, API supply, licensing, contract research, biosimilars and partnerships in vaccines and specialty drugs. In India, the company combines branded prescription medicines with broader affordable-medicine programs, while in overseas markets it typically competes through regulatory filings, manufacturing capability and portfolio breadth. In 2020, Dr. Reddy's partnered with the Russian Direct Investment Fund on clinical development, regulatory work, manufacturing and distribution of the Sputnik V vaccine in India. The vaccine received emergency-use authorization in India in April 2021. In 2024, the company announced a partnership with Pharmazz to bring centhaquine, marketed as Lyfaquin, to India. The brand is currently associated with affordable medicine access, vertically integrated pharmaceutical capabilities and international generic competition, while continuing to operate in mature products and selected high-value therapies.

History

Dr. Reddy's Laboratories began operations in 1984 as an API manufacturer. Its founder, Kallam Anji Reddy, had prior experience in India's public pharmaceutical sector. The company moved into finished and branded formulations in 1986 and soon introduced products such as Norilet and Omez. Omez became particularly significant because its lower-price positioning helped establish the company's Indian branded-prescription business. The company first expanded internationally by exporting APIs and finished products to markets where regulatory barriers were less demanding. This generated the scale needed to invest in facilities capable of meeting U.S. and European requirements. In 1987 it began shifting from being primarily a supplier to other manufacturers toward producing finished pharmaceutical products. It entered Russia in 1992 through a joint venture with Biomed, but exited the venture in 1995 after reported allegations concerning losses and the conduct of the Moscow operation. It also established Middle Eastern and Russian formulation operations during the early 1990s. Research became a central part of the company's long-term strategy. The Dr. Reddy's Research Foundation was established in 1992, and a U.S. discovery laboratory, Reddy US Therapeutics, was created in Atlanta in 2000. The company explored new chemical entities and specialty therapies in areas including oncology, diabetes, cardiovascular disease and infection, while using specialty generics as a bridge between conventional generic manufacturing and innovative drug development. Aurigene Discovery Technologies was established as a wholly owned contract-research subsidiary in 2002. By the late 1990s Dr. Reddy's was filing U.S. abbreviated new drug applications and using patent challenges to pursue early generic entry. It acquired American Remedies in 1999 and merged Cheminor Drug with its operations, strengthening its Indian finished-dose and API businesses. In 2000 it made its first commercial U.S. generic launch, followed by an exclusivity launch in 2001. The same year it listed American Depositary Receipts on the New York Stock Exchange. Its generic fluoxetine launch, covering a dosage form not secured by Barr Laboratories' competing exclusivity position, followed successful litigation against patents associated with Prozac and generated substantial initial sales. International acquisitions then broadened the platform. BMS Laboratories and Meridian Healthcare were acquired in the United Kingdom in 2002, Trigenesis Therapeutics was acquired in 2004 to add dermatology technology, and Betapharm Arzneimittel was acquired in 2006, giving the company a significant German generics presence. The company also entered research and commercialization agreements with firms including Novo Nordisk, Argenta Discovery, Rheoscience and Eurodrug Laboratories. Not every development program succeeded: a patent challenge involving Pfizer's Norvasc was unsuccessful and imposed costs on the specialty-generics strategy. Dr. Reddy's continued to combine internal development with acquisitions and licensing. In 2015 it purchased established UCB brands in South Asia and licensed U.S. development and commercialization rights for XenoPort's XP23829. During the COVID-19 pandemic it partnered with the Russian Direct Investment Fund on Sputnik V trials and Indian supply. The vaccine received emergency authorization in April 2021. In March 2024 the company announced a partnership with Pharmazz concerning centhaquine in India. Across its history, the business has remained centered on affordable medicines, APIs, regulated-market generics and selected specialty, biosimilar and innovative-product opportunities.

2024
Centhaquine partnership
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
Dr. Reddy's partnered with Pharmazz to bring centhaquine, or Lyfaquin, to India.
2021
Sputnik V authorized in India
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
India granted emergency-use authorization to Sputnik V after late-stage evaluation.
2020
Sputnik V partnership
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
The company partnered with RDIF for Sputnik V clinical development and Indian supply.
2006
Betapharm acquisition
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
Dr. Reddy's acquired German generics company Betapharm Arzneimittel.
2002
UK expansion
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
BMS Laboratories and Meridian Healthcare were acquired, adding UK oral-solid, liquid and packaging capabilities.
2001
NYSE listing and fluoxetine launch
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
The company listed on the New York Stock Exchange and launched generic fluoxetine in the United States with 180-day exclusivity for one dosage form.
2000
First commercial U.S. generic launch
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
Dr. Reddy's launched its first commercial generic product in the United States.
1999
American Remedies acquisition
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
The acquisition strengthened the company's Indian manufacturing and product portfolio.
1992
Research foundation established
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
The Dr. Reddy's Research Foundation was created to support drug-discovery work.
1987
First European API exports
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
Dr. Reddy's became the first Indian company described in the reference history to export pharmaceutical APIs to Europe.
1986
Entry into branded formulations
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
The company began operations in branded pharmaceutical formulations.
1984
Company founded
[1]Dr. Reddy's Laboratoriesen.wikipedia.org
Kallam Anji Reddy founded Dr. Reddy's Laboratories in Hyderabad, initially focusing on active pharmaceutical ingredients.

Products and positioning

Affordable, quality-focused medicines supported by vertically integrated manufacturing, regulatory expertise and international distribution.

Branded formulation
Omez
Omez is Dr. Reddy's branded omeprazole product for acid-related gastrointestinal conditions, including ulcers and reflux-related disease. Its launch in India was important to the company's transition from API supply into branded formulations because it used a lower-price proposition against established competing brands.
Generic pharmaceutical · 2001
Generic fluoxetine
Dr. Reddy's generic fluoxetine, a version of the medicine associated with Prozac, was launched in the United States in 2001. The company obtained 180-day exclusivity for one approved dosage form after prevailing in patent litigation, making the product a landmark in its regulated-market generic strategy.
API portfolio · 1984
Active pharmaceutical ingredients
APIs were the company's original commercial foundation and remain a major capability. Dr. Reddy's supplies ingredients used by pharmaceutical manufacturers and has developed manufacturing and regulatory systems intended to serve both domestic and demanding international markets.
Biotechnology and specialty pharmaceuticals
Biosimilars and specialty products
The company operates in higher-value areas alongside conventional generics, including biosimilars, specialty formulations and products for selected therapeutic niches. These businesses extend its portfolio beyond commodity API supply and support its broader international strategy.

Controversies

2021
Novartis and Dana-Farber sue Dr. Reddy’s over generic Rydapt
Novartis Pharmaceuticals and Dana-Farber Cancer Institute filed a complaint alleging that Dr. Reddy’s Laboratories infringed Novartis’s patent for Rydapt through its proposed generic leukemia treatment. The allegations are claims in the lawsuit, not a court finding.
Source
2021
Dr. Reddy's recalls prescription drug blister packages
Dr. Reddy's recalled approximately 21,400 blister packages of specified prescription medications because the packaging was not child resistant and could pose a poisoning risk if young children swallowed the contents. No incidents or injuries had been reported.
Source
2020
Dr. Reddy’s recalls Esomeprazole Magnesium capsules
Dr. Reddy’s Laboratories voluntarily recalled 1,752 bottles of generic Esomeprazole Magnesium delayed-release capsules in the United States. According to the report, the recall followed the USFDA's identification of discoloration and brown pellets in the product. The report describes the action as a Class III recall.
Source
2020
Dr. Reddy's and Celgene settle Revlimid patent litigation
Dr. Reddy's Laboratories announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy's to sell volume-limited generic lenalidomide capsules in the United States beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026. The announcement described the licensed sales as volume-limited until the later date, when the volume limitation would no longer apply.
Source
2020
Dr. Reddy's Laboratories discloses ransomware attack
Dr. Reddy's Laboratories stated that the cyber attack it had detected the previous week involved ransomware. The company said it had isolated the impacted IT services. It also said its investigation had not determined whether any data breach involved personally identifiable information.
Source
2019
Court denies Dr. Reddy’s summary judgment motion in VIMOVO patent litigation
The United States District Court for the District of New Jersey denied a motion for summary judgment filed by Dr. Reddy’s Laboratories in Nuvo-related litigation over two VIMOVO patents, so the patent infringement litigation would continue. Nuvo said it believed the patents were valid and enforceable; the court decision reported here concerned the motion, not a final determination of infringement.
Source
2019
Dr. Reddy's recalls ranitidine lots in the US
Dr. Reddy's initiated a voluntary recall of several lots of its ranitidine products in the US after confirmed contamination with NDMA above levels established by the FDA. The recall began on October 1.
Source
1995
Russian joint-venture controversy
Dr. Reddy's exited its Russian joint venture with Biomed amid reported allegations involving a significant material loss and activities connected with the Moscow branch and Biomed's chief executive. The venture was subsequently sold to the Sistema group.
Source

2024
Pharmazz centhaquine partnershipOther
Background
Pharmazz was developing centhaquine, a therapy intended for use in acute blood-loss situations.
Action taken
Dr. Reddy's partnered with Pharmazz to bring centhaquine, marketed as Lyfaquin, to India.
Source
2020
Sputnik V development and supply partnershipStrategy
Background
The COVID-19 pandemic created demand for vaccine development and manufacturing partnerships in India.
Action taken
Dr. Reddy's partnered with RDIF to conduct phase 3 trials and support manufacture and distribution of Sputnik V in India.
Aftermath
The vaccine received Indian emergency-use authorization in April 2021.
Source
2001
Launch of generic fluoxetine in the United StatesProduct launch
Background
The company pursued a U.S. generic opportunity connected with Prozac patents and secured rights for one dosage form after litigation.
Action taken
Dr. Reddy's launched generic fluoxetine with 180-day market exclusivity for the approved dosage form.
Aftermath
The launch generated substantial initial revenue and became a defining example of the company's patent-challenge strategy.
Source

Recent events

2022.02.24
Reported2022.02.25
Dr. Reddy's completes acquisition of Nimbus Health[10]Dr. Reddy's完成对Nimbus Health的收购business-standard.com
Dr. Reddy's Laboratories completed its acquisition of Nimbus Health GmbH. Nimbus Health became a wholly owned step-down subsidiary of Dr. Reddy's with effect from 24 February 2022.
2022.01.04
Reported2022.01.04
Dr Reddy's launches Molflu in India[11]Dr Reddy's 在印度推出 Molflubusinesstoday.in
Dr Reddy's Laboratories launched molnupiravir capsules under the Molflu brand in India at Rs 35 per capsule. The company said the product was expected to become available in pharmacies from early the following week.
2021.09.07
Reported2021.09.07
Mintop launches minoxidil treatment for female pattern hair loss in India[12]Mintop在印度推出女性型脱发米诺地尔治疗产品business-standard.com
Dr. Reddy's announced the launch of minoxidil products for women under the Mintop and Mintop Eva brand names following India's first approval of the treatment indication for female pattern hair loss.
2021.07.30
Reported2021.08.03
Novartis and Dana-Farber sue Dr. Reddy’s over generic Rydapt[7]Novartis and Dana-Farber sue Dr. Reddy’s over generic Rydaptlawstreetmedia.com
Novartis Pharmaceuticals and Dana-Farber Cancer Institute filed a complaint alleging that Dr. Reddy’s Laboratories infringed Novartis’s patent for Rydapt through its proposed generic leukemia treatment. The allegations are claims in the lawsuit, not a court finding.
2021.06.28
Reported2021.06.28
Dr Reddy's announces commercial launch of 2-DG[13]Dr Reddy's宣布2-DG商业上市economictimes.indiatimes.com
Dr Reddy's Laboratories announced the commercial launch of 2-DG, a COVID-19 treatment drug, at a maximum retail price of Rs 990 per sachet. It said initial availability would be in hospitals across metros and Tier 1 cities, followed by expansion to the rest of India.
2021.06.18
Reported2021.06.18
Aster DM Healthcare partners with Dr Reddy's to administer Sputnik V[14]Aster DM Healthcare与Dr Reddy's合作接种Sputnik V疫苗thehindu.com
Aster DM Healthcare said it had partnered with Dr Reddy's Laboratories to administer Sputnik V in a limited pilot soft launch, initially in Kochi, Kerala, and Kolhapur, Maharashtra.
2021.06.09
Reported2021.06.09
Rockwell and Dr. Reddy’s partner on vaccine freezers[15]Rockwell与Dr. Reddy’s合作提供疫苗冰柜aninews.in
Rockwell Industries joined hands with Dr. Reddy’s Laboratories to provide WHO PQS-certified Covid-19 vaccine freezers for storage of the Sputnik V vaccine across India.
2021.05.17
Reported2021.05.17
First batch of 2-DG COVID-19 medicine released[16]首批2-DG新冠药物发布indiatvnews.com
The first batch of the 2-deoxy-D-glucose (2-DG) COVID-19 drug, developed by DRDO in collaboration with Dr Reddy's Laboratories, was released by India's defence minister.
2021.03.31
Reported2021.03.31
Dr. Reddy's Laboratories enters partnership agreement with ABCD Technologies[17]Dr. Reddy's Laboratories与ABCD Technologies签订合作协议business-standard.com
Dr. Reddy's Laboratories entered into a partnership agreement with ABCD Technologies LLP, which is to be renamed IndoHealth Services LLP.
2021.02.25
Reported2021.02.25
Dr. Reddy's recalls prescription drug blister packages[8]Dr. Reddy's recalls prescription drug blister packagesprnewswire.com
Dr. Reddy's recalled approximately 21,400 blister packages of specified prescription medications because the packaging was not child resistant and could pose a poisoning risk if young children swallowed the contents. No incidents or injuries had been reported.

Sources117 sources

Cite this profile: Cite the canonical profile. /brand-wiki/dr-reddys-laboratories · Editorial policy · How profiles are compiled